NeuBase Therapeutics, Inc

(NASDAQ:NBSE)

Latest On NeuBase Therapeutics, Inc (NBSE):

Date/Time Type Description Signal Details
2023-05-11 22:40 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02N/A
2023-02-15 00:46 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.13 misses by $0.02N/A
2022-12-22 01:26 ESTNewsNeuBase Therapeutics GAAP EPS of -$1.04 beats by $0.04N/A
2022-10-21 10:11 ESTNewsNeuBase stock rises on gene editing research collaborationN/A
2022-10-14 20:22 ESTNewsNeuBase Therapeutics announces restructuring, to cut 60% of workforceN/A
2022-08-11 13:00 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04N/A
2022-06-29 20:38 ESTNewsNeuBase Therapeutics promotes Dr. William Mann to President and COON/A
2022-05-12 21:21 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.30 misses by $0.06N/A
2022-02-11 06:41 ESTNewsNeuBase Therapeutics GAAP EPS of -$0.24N/A
2022-01-10 23:06 ESTNewsNeuBase Therapeutics names Phathom's Todd Branning as new CFON/A
2021-12-27 17:13 ESTNewsNeuBase Therapeutics reports FY resultsN/A
2021-10-25 22:31 ESTNewsWarning: NBSE is at high risk of performing badlyN/A
2021-08-12 21:20 ESTNewsNeuBase Therapeutics EPS misses by $0.07N/A
2021-04-22 19:23 ESTNewsNeuBase Therapeutics stock continues slumping, prices $40M public offeringN/A
2021-04-21 22:21 ESTNewsNeuBase Therapeutics slumps on launching stock offeringN/A
2021-03-18 23:20 ESTNewsNeubase Therapeutics (NBSE) Investor Presentation - SlideshowN/A
2021-03-16 21:30 ESTAnalyst RatingThe Analyst Target Price has increased from $16.8 to $17.Buy
2021-02-19 04:10 ESTAnalyst RatingThe Analyst Target Price has increased from $16.17 to $16.8.Buy
2021-02-15 12:04 ESTAnalyst RatingThe Analyst Target Price has increased from $15.67 to $16.17.Buy
2021-02-12 12:02 ESTEarnings EstimateAn EPS average of -$0.24 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-12 04:22 ESTNewsNeuBase Therapeutics EPS beats by $0.05N/A
2021-02-12 04:11 ESTFinancialsCompany financials have been released.Neutral
2021-01-28 10:43 ESTNewsNeuBase snaps gene modulating technology from Vera TherapeuticsN/A
2021-01-21 12:10 ESTNewsAssured Guaranty falls as Greenlight reveals short in new investor letterN/A
2021-01-06 16:16 ESTFinancialsCompany financials have been released.Neutral
2020-12-25 08:33 ESTAnalyst RatingThe Analyst Target Price has increased from $15.2 to $15.67.Buy
2020-12-25 00:39 ESTFinancialsCompany financials have been released.Neutral
2020-12-24 16:24 ESTEarnings EstimateAn EPS average of -$1.19 is estimated for the 2022 year.Sell
2020-12-24 16:24 ESTEarnings EstimateAn EPS average of -$0.25 is estimated for the quarter ending on March 31, 2021.Sell
2020-12-24 16:24 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.67 to $15.2.Neutral
2020-12-23 16:39 ESTNewsNeuBase Therapeutics EPS in-lineN/A
2020-12-16 09:24 ESTNewsNeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophyN/A
2020-11-26 20:56 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:34 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:30 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-31 17:08 ESTFinancialsCompany financials have been released.Neutral
2020-08-29 09:06 ESTFinancialsCompany financials have been released.Neutral
2020-08-25 17:22 ESTFinancialsCompany financials have been released.Neutral
2020-08-22 05:10 ESTFinancialsCompany financials have been released.Neutral
2020-08-17 21:25 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 17:17 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:33 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 05:16 ESTEarnings EstimateAn EPS average of -$0.24 is estimated for the quarter ending on December 31, 2020.Sell
2020-08-13 23:18 ESTNewsNeuBase Therapeutics reports FQ3 resultsN/A
2020-08-06 21:24 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 02:24 ESTNewsNeuBase Therapeutics appoints industry veteran as COON/A

About NeuBase Therapeutics, Inc (NBSE):

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Quotes by TradingView

See Advanced Chart

General

  • Name NeuBase Therapeutics, Inc
  • Symbol NBSE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 15
  • Fiscal Year EndSeptember
  • IPO Date2007-05-01
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.neubasetherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 7.53
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.88
  • Next Year EPS Estimate -$1.23
  • Next Quarter EPS Estimate -$0.24
  • Return on Assets -55%
  • Return on Equity -95%
  • Earnings Per Share -$0.12
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 198.87 million
  • Analyst Target Price $17
  • Book Value Per Share $0.59
View More

Share Statistics

  • Shares Outstanding 23.18 million
  • Shares Float 17.6 million
  • % Held by Insiders 1707%
  • % Held by Institutions 31.94%
  • Shares Short 881734
  • Shares Short Prior Month 805036
  • Short Ratio 2.72
  • Short % of Float 4%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • 52 Week High $12.89
  • 52 Week Low $4.52
  • 50 Day Moving Average 10
  • 200 Day Moving Average 8.57
View More

Dividends

  • Dividend Date 2019-02-04
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

NeuBase Therapeutics, Inc (NBSE) Dividend Calendar:

NBSE's last dividend payment was made to shareholders on February 4, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

NeuBase Therapeutics, Inc (NBSE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.18-$0.2423.4%
2020-09-302020-12-23$N/A-$0.20-$0.20-0.86%
2020-06-302020-08-13$N/A-$0.18-$0.2320.6%
2020-03-312020-05-14$N/A-$0.26-$0.22-16.85%
2019-12-312020-03-26$N/A-$0.26-$0.3628.43%
2019-09-302019-09-30$N/A-$2.14-$0.28-664.29%
2019-06-302019-08-14$N/A-$0.40
2019-03-312019-05-15$N/A-$0.40
2018-12-312019-01-03$N/A-$0.32
2018-09-302018-12-15-$2.25
2018-06-302018-08-14-$0.19
2018-03-312018-05-15-$1.00-$1.4028.57%
2017-12-312018-02-14-$1.40-$1.400%
2017-09-302017-12-15-$1.60-$1.600%
2017-06-302017-08-08-$1.45
2017-03-312017-05-11-$0.21-$0.3030%
2016-12-312017-02-14-$0.21-$0.19-10.53%
2016-09-302016-12-22$N/A-$0.21-$0.2412.5%
2016-06-302016-08-09$N/A-$0.24-$0.2711.11%
2016-03-312016-05-10$N/A-$0.17-$0.185.56%
2015-12-312016-02-09$N/A-$0.20-$0.2416.67%
2015-09-302015-12-10$N/A-$0.13-$0.1931.58%
2015-06-302015-08-06$N/A-$0.11-$0.1838.89%
2015-03-312015-05-11$N/A-$0.12-$0.1833.33%
2014-12-312015-02-09$N/A-$0.18-$0.2010%
2014-09-302014-12-22$N/A-$0.12-$0.10-20%
2014-06-302014-08-18$N/A-$1.80-$2.0010%
2014-03-312014-05-13$N/A-$2.00-$2.4016.67%
2013-12-312014-02-14$N/A-$2.00-$2.000%
2013-09-302013-12-27-$1.40-$1.400%
2013-06-302013-08-13-$1.40-$0.80-75%
2013-03-312013-05-14-$0.60-$1.2050%
2012-12-312013-01-09-$1.80-$0.60-200%
2012-06-302012-08-29-$0.66
2012-03-312012-05-30-$2.04
2011-12-312011-12-31$0.40
2011-09-302011-09-30-$2.11
2011-06-302011-06-30-$4.74
2011-03-312011-03-31-$0.24
2010-12-312010-12-31-$0.76
2010-09-302010-09-30$6.53
2010-06-302010-06-30-$0.30
2010-03-312010-03-31-$5.24
2009-12-312009-12-31-$0.38
2009-09-302009-09-30-$0.30
2009-06-302009-06-30-$0.49
2009-03-312009-03-31-$1.06
2008-12-312008-12-31-$0.16
2008-09-302008-09-30-$0.67
2008-06-302008-06-30$0.02
2008-03-312008-03-31-$0.22
2007-12-312007-12-31$0.75
2007-09-302007-09-30-$0.46
2007-06-302007-06-30-$7.68
2007-03-312007-03-31-$51.37
2006-12-312006-12-31$0.60
2006-09-302006-09-30-$0.38
2006-06-302006-06-30$1.92
2006-03-312006-03-31$0.90
2005-12-312005-12-31-$0.83
2005-09-302005-09-30$1.70
2005-06-302005-06-30-$0.62
2005-03-312005-03-31$1.30
2004-12-312004-12-31$4.80
2004-09-302004-09-30$1.01
2004-06-302004-06-30$1.89

NeuBase Therapeutics, Inc (NBSE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

NeuBase Therapeutics, Inc (NBSE) Chart:

NeuBase Therapeutics, Inc (NBSE) News:

Below you will find a list of latest news for NeuBase Therapeutics, Inc (NBSE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

NeuBase Therapeutics, Inc (NBSE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2032-10-2150PUT 0TRUE00

Latest NBSE Trades:

Date Shares Price
Jun 13, 2022 3:43 PM EST100$0.9323
Jun 13, 2022 3:43 PM EST100$0.9188
Jun 13, 2022 3:43 PM EST100$0.9127
Jun 13, 2022 3:43 PM EST100$0.9127

NeuBase Therapeutics, Inc (NBSE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1173281/000110465920079797/0001104659-20-079797-index.htm
2019-04-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019006762/0000000000-19-006762-index.htm
2019-05-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019007949/0000000000-19-007949-index.htm
2019-05-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019008674/0000000000-19-008674-index.htm
2019-09-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1173281/000000000019013774/0000000000-19-013774-index.htm
2019-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000092963819000683/0000929638-19-000683-index.htm
2019-12-31NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1173281/000110465919077303/0001104659-19-077303-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920002674/0001104659-20-002674-index.htm
2020-01-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1173281/000110465920003043/0001104659-20-003043-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920020287/0001104659-20-020287-index.htm
2020-02-14NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1173281/000110465920022019/0001104659-20-022019-index.htm
2020-02-188-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920022491/0001104659-20-022491-index.htm
2020-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920023939/0001104659-20-023939-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920038784/0001104659-20-038784-index.htm
2020-03-268-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920038899/0001104659-20-038899-index.htm
2020-03-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920038903/0001104659-20-038903-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920040873/0001104659-20-040873-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920043210/0001104659-20-043210-index.htm
2020-04-038-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920043215/0001104659-20-043215-index.htm
2020-04-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920051617/0001104659-20-051617-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920052567/0001104659-20-052567-index.htm
2020-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920053403/0001104659-20-053403-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920054436/0001104659-20-054436-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920055957/0001104659-20-055957-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920056066/0001104659-20-056066-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920056110/0001104659-20-056110-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920056160/0001104659-20-056160-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920061594/0001104659-20-061594-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920061711/0001104659-20-061711-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920065897/0001104659-20-065897-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920071404/0001104659-20-071404-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920071857/0001104659-20-071857-index.htm
2020-07-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920079774/0001104659-20-079774-index.htm
2020-07-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1173281/000110465920079797/0001104659-20-079797-index.htm
2020-07-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920087039/0001104659-20-087039-index.htm
2020-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920087336/0001104659-20-087336-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920087347/0001104659-20-087347-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920094366/0001104659-20-094366-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920094671/0001104659-20-094671-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000110465920094763/0001104659-20-094763-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104478/0001104659-20-104478-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104488/0001104659-20-104488-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104489/0001104659-20-104489-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104491/0001104659-20-104491-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000110465920104493/0001104659-20-104493-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000110465920112440/0001104659-20-112440-index.htm
2018-01-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000058/0001387131-18-000058-index.htm
2018-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000666/0001387131-18-000666-index.htm
2018-02-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713118000667/0001387131-18-000667-index.htm
2018-02-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000710/0001387131-18-000710-index.htm
2018-02-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118000769/0001387131-18-000769-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118002194/0001387131-18-002194-index.htm
2018-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713118002211/0001387131-18-002211-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004003/0001387131-18-004003-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713118004016/0001387131-18-004016-index.htm
2018-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004183/0001387131-18-004183-index.htm
2018-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004298/0001387131-18-004298-index.htm
2018-09-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118004559/0001387131-18-004559-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713118005225/0001387131-18-005225-index.htm
2018-12-07PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118006691/0001387131-18-006691-index.htm
2018-12-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1173281/000138713118006826/0001387131-18-006826-index.htm
2018-12-31NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1173281/000138713118007126/0001387131-18-007126-index.htm
2019-01-0310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1173281/000138713119000051/0001387131-19-000051-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000062/0001387131-19-000062-index.htm
2019-01-03425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000063/0001387131-19-000063-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000419/0001387131-19-000419-index.htm
2019-01-23425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119000420/0001387131-19-000420-index.htm
2019-02-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119001277/0001387131-19-001277-index.htm
2019-02-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001282/0001387131-19-001282-index.htm
2019-02-15425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001283/0001387131-19-001283-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001453/0001387131-19-001453-index.htm
2019-03-08S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119001802/0001387131-19-001802-index.htm
2019-04-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119002689/0001387131-19-002689-index.htm
2019-04-16S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119002690/0001387131-19-002690-index.htm
2019-05-07S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003388/0001387131-19-003388-index.htm
2019-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003390/0001387131-19-003390-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003726/0001387131-19-003726-index.htm
2019-05-15425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003727/0001387131-19-003727-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119003729/0001387131-19-003729-index.htm
2019-05-22S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003888/0001387131-19-003888-index.htm
2019-05-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119003889/0001387131-19-003889-index.htm
2019-06-03S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004175/0001387131-19-004175-index.htm
2019-06-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004220/0001387131-19-004220-index.htm
2019-06-06424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119004248/0001387131-19-004248-index.htm
2019-07-02425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004795/0001387131-19-004795-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004832/0001387131-19-004832-index.htm
2019-07-03425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004833/0001387131-19-004833-index.htm
2019-07-08425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004892/0001387131-19-004892-index.htm
2019-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004960/0001387131-19-004960-index.htm
2019-07-10425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004961/0001387131-19-004961-index.htm
2019-07-118-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004992/0001387131-19-004992-index.htm
2019-07-11425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119004993/0001387131-19-004993-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005021/0001387131-19-005021-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005123/0001387131-19-005123-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005124/0001387131-19-005124-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005125/0001387131-19-005125-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005126/0001387131-19-005126-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005127/0001387131-19-005127-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005128/0001387131-19-005128-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005129/0001387131-19-005129-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005130/0001387131-19-005130-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005131/0001387131-19-005131-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005132/0001387131-19-005132-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005133/0001387131-19-005133-index.htm
2019-07-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005158/0001387131-19-005158-index.htm
2019-07-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005251/0001387131-19-005251-index.htm
2019-07-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005253/0001387131-19-005253-index.htm
2019-07-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1173281/000138713119005254/0001387131-19-005254-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119006142/0001387131-19-006142-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119006165/0001387131-19-006165-index.htm
2019-08-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1173281/000138713119006228/0001387131-19-006228-index.htm
2019-09-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1173281/000138713119006938/0001387131-19-006938-index.htm
2019-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1173281/000138713119007028/0001387131-19-007028-index.htm
2019-09-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1173281/000138713119007087/0001387131-19-007087-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119007089/0001387131-19-007089-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1173281/000138713119007419/0001387131-19-007419-index.htm
2020-05-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000138713120004350/0001387131-20-004350-index.htm
2019-07-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000153538419000009/0001535384-19-000009-index.htm
2019-08-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1173281/000178640619000001/0001786406-19-000001-index.htm
2019-06-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1173281/999999999519001291/9999999995-19-001291-index.htm
2019-09-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1173281/999999999519002155/9999999995-19-002155-index.htm
2019-06-07CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1173281/999999999719005367/9999999997-19-005367-index.htm

NeuBase Therapeutics, Inc (NBSE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of NeuBase Therapeutics, Inc (NBSE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1707%
Institutional Ownership: 3194%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-30Dietrich A StephanPresident and CEOBuy10,000.006.0060,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920056160/0001104659-20-056160-index.htm
2020-04-30DOV A MD GOLDSTEINDirectorBuy10,000.006.0060,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920056110/0001104659-20-056110-index.htm
2020-05-21Dietrich A StephanPresident and CEOBuy1,250.008.0910,111.0011,250.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920065897/0001104659-20-065897-index.htm
2020-04-30Samuel BackenrothCFO, Treasurer & SecretaryBuy1,000.006.006,000.0011,630.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920056066/0001104659-20-056066-index.htm
2020-06-09Dietrich A StephanPresident and CEOBuy1,275.007.739,860.7212,525.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920071857/0001104659-20-071857-index.htm
2019-07-12ERIC I RICHMANDirectorBuy25,247.0025,247.00https://www.sec.gov/Archives/edgar/data/1173281/000138713119005131/0001387131-19-005131-index.htm
2019-07-12Dietrich A StephanPresident and CEOBuy2,547,639.002,547,639.00https://www.sec.gov/Archives/edgar/data/1173281/000138713119005132/0001387131-19-005132-index.htm
2020-04-30ERIC I RICHMANDirectorBuy2,500.006.0015,000.0027,747.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920055957/0001104659-20-055957-index.htm
2020-04-30ERIC I RICHMANDirectorBuy8,333.006.0049,998.0036,080.00https://www.sec.gov/Archives/edgar/data/1173281/000110465920055957/0001104659-20-055957-index.htm